AYTU BIOPHARMA, INC Cost of Revenue
AYTU BIOPHARMA, INC (AYTU) reported Cost of Revenue of $20.75 million for the 12-month period ending 2026-06-30, per its 10-K filed 2026-09-22.
Financial Statements › Expense Statement › Cost of Sales
us-gaap:CostOfGoodsAndServicesSold · last filed 2026-09-22
- AYTU BIOPHARMA, INC cost of goods and services sold for the quarter ending 2026-06-30 was $5.70M, a 16.72% increase year-over-year.
- AYTU BIOPHARMA, INC cost of goods and services sold for the quarter ending 2026-03-31 was $4.81M, a 14.77% decline year-over-year.
- AYTU BIOPHARMA, INC cost of goods and services sold for the quarter ending 2025-12-31 was $5.54M, a 1.95% increase year-over-year.
- AYTU BIOPHARMA, INC cost of goods and services sold for the quarter ending 2025-09-30 was $4.70M, a 2.46% increase year-over-year.
- AYTU BIOPHARMA, INC cost of goods and services sold for fiscal 2026 was $20.75M, a 0.98% increase from fiscal 2025.
- AYTU BIOPHARMA, INC cost of goods and services sold for fiscal 2025 was $20.55M, a 27.42% increase from fiscal 2024.
- AYTU BIOPHARMA, INC cost of goods and services sold for fiscal 2024 was $16.13M, a 60.44% decline from fiscal 2023.
- AYTU BIOPHARMA, INC cost of goods and services sold for fiscal 2023 was $40.77M, a 8.15% decline from fiscal 2022.
| Period end | Cost of Goods and Services Sold 3 month | Cost of Goods and Services Sold 3 month as first filed | Cost of Goods and Services Sold 6 month | Cost of Goods and Services Sold 6 month as first filed | Cost of Goods and Services Sold 9 month | Cost of Goods and Services Sold 9 month as first filed | Cost of Goods and Services Sold 12 month | Cost of Goods and Services Sold 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $5.70M derived: 10-K 12 month − 10-Q 9 month · filed 2026-09-22 | $10.51M derived: sum of 2 quarters · filed 2026-09-22 | $16.05M derived: sum of 3 quarters · filed 2026-09-22 | $20.75M 10-K · filed 2026-09-22 | ||||
| 2026-03-31 | $4.81M 10-Q · filed 2026-05-13 | $10.35M derived: sum of 2 quarters · filed 2026-05-13 | $15.05M 10-Q · filed 2026-05-13 | $19.94M derived: sum of 4 quarters · filed 2026-09-22 | ||||
| 2025-12-31 | $5.54M 10-Q · filed 2026-02-03 | $10.24M 10-Q · filed 2026-02-03 | $15.12M derived: sum of 3 quarters · filed 2026-09-22 | $20.77M derived: sum of 4 quarters · filed 2026-09-22 | ||||
| 2025-09-30 | $4.70M 10-Q · filed 2025-11-13 | $9.58M derived: sum of 2 quarters · filed 2026-09-22 | $15.23M derived: sum of 3 quarters · filed 2026-09-22 | $20.66M derived: sum of 4 quarters · filed 2026-09-22 | ||||
| 2025-06-30 | $4.88M derived: 10-K 12 month − 10-Q 9 month · filed 2026-09-22 | $10.53M derived: sum of 2 quarters · filed 2026-09-22 | $15.96M derived: sum of 3 quarters · filed 2026-09-22 | $20.55M 10-K · filed 2026-09-22 | ||||
| 2025-03-31 | $5.65M 10-Q · filed 2026-05-13 | $11.08M derived: sum of 2 quarters · filed 2026-05-13 | $15.67M 10-Q · filed 2026-05-13 | $19.21M derived: sum of 4 quarters · filed 2026-05-13 | ||||
| 2024-12-31 | $5.43M 10-Q · filed 2026-02-03 | $10.02M 10-Q · filed 2026-02-03 | $13.56M derived: sum of 3 quarters · filed 2026-02-03 | $17.23M derived: sum of 4 quarters · filed 2026-02-03 | ||||
| 2024-09-30 | $4.59M 10-Q · filed 2025-11-13 | $8.13M derived: sum of 2 quarters · filed 2025-11-13 | $11.79M derived: sum of 3 quarters · filed 2025-11-13 | $15.94M derived: sum of 4 quarters · filed 2025-11-13 | ||||
| 2024-06-30 | $3.54M derived: 10-K 12 month − 10-Q 9 month · filed 2025-09-23 | $7.21M derived: sum of 2 quarters · filed 2025-09-23 | $11.35M derived: sum of 3 quarters · filed 2025-09-23 | $16.13M 10-K · filed 2025-09-23 | $26.42M 10-K · filed 2024-09-26 | |||
| 2024-03-31 | $3.66M 10-Q · filed 2025-05-14 | $6.30M 10-Q · filed 2024-05-15 | $7.81M derived: sum of 2 quarters · filed 2025-05-14 | $12.59M 10-Q · filed 2025-05-14 | $20.35M 10-Q · filed 2024-05-15 | $24.76M derived: sum of 4 quarters · filed 2025-05-14 | ||
| 2023-12-31 | $4.14M 10-Q · filed 2025-02-12 | $6.73M 10-Q · filed 2024-02-14 | $8.92M 10-Q · filed 2025-02-12 | $14.05M 10-Q · filed 2024-02-14 | $21.09M derived: sum of 3 quarters · filed 2025-02-12 | $31.08M derived: sum of 4 quarters · filed 2025-02-12 | ||
| 2023-09-30 | $4.78M 10-Q · filed 2024-11-13 | $7.32M 10-Q · filed 2023-11-14 | $16.95M derived: sum of 2 quarters · filed 2024-11-13 | $26.94M derived: sum of 3 quarters · filed 2024-11-13 | $35.92M derived: sum of 4 quarters · filed 2024-11-13 | |||
| 2023-06-30 | $12.17M derived: 10-K 12 month − 10-Q 9 month · filed 2024-09-26 | $22.16M derived: sum of 2 quarters · filed 2024-09-26 | $31.14M derived: sum of 3 quarters · filed 2024-09-26 | $40.77M 10-K · filed 2024-09-26 | ||||
| 2023-03-31 | $9.99M 10-Q · filed 2024-05-15 | $18.98M derived: sum of 2 quarters · filed 2024-05-15 | $28.60M 10-Q · filed 2024-05-15 | |||||
| 2022-12-31 | $8.99M 10-Q · filed 2024-02-14 | $18.61M 10-Q · filed 2024-02-14 | ||||||
| 2022-09-30 | $9.62M 10-Q · filed 2023-11-14 | |||||||
| 2022-06-30 | $44.39M 10-K · filed 2023-10-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |
| ARTELO BIOSCIENCES, INC. (ARTL) | United States | $0.023B | |
| KYNTRA BIO, INC. (KYNB) | United States | $0.028B | 0.17 |
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| Hepion Pharmaceuticals, Inc. (HEPA) | United States | $0.029B | -0.62 |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| IGC Pharma, Inc. (IGC) | United States | $0.029B | -5.98 |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |